Department of Clinical Sciences Lund, Cardiothoracic Surgery.
Department of Clinical Sciences Lund, Surgery, Lund University and Skåne University Hospital, Lund, Sweden.
J Heart Lung Transplant. 2015 Jul;34(7):892-8. doi: 10.1016/j.healun.2015.01.008. Epub 2015 Jan 16.
In the past, ABO incompatibility was considered an absolute contraindication to heart transplantation (HT) in adults. Advances in ABO-incompatible HT in pediatric patients and ABO-incompatible abdominal transplantation in adult patients have led to clinical exploration of intentional ABO-incompatible HT in adults. However, it is not well known how outcomes in ABO-incompatible adult heart transplant recipients compare with outcomes in ABO-compatible recipients.
We analyzed International Society for Heart and Lung Transplantation transplant registry data from heart donors and recipients ≥18 years old at the time of transplant for HT performed between 1988 and 2011. We compared baseline characteristics and post-transplant outcomes in ABO-incompatible and ABO-compatible HT. Death or retransplantation was the composite primary end-point.
Among 76,663 adult patients undergoing HT between 1988 and June 30, 2011, 94 ABO-incompatible heart transplants were performed. The incidence of death or retransplantation in the ABO-incompatible group was higher than in the ABO-compatible group: 21% vs 9% at 30 days (hazard ratio = 2.38, p < 0.001) and 36% vs 19% at 1 year after transplant. However, ABO-incompatible grafts surviving past the first year after transplant had a similar incidence of failure compared with the ABO-compatible group. After 2005, the rate ABO-incompatible HT in adults increased, likely as a result of planned, intentional (rather than accidental) ABO-incompatible HT. In this group of patients, short-term and long-term incidence of death or retransplantation was similar to ABO-compatible recipients (p = 0.822): 7% at 30 days and 19% at 1 year after transplantation.
We found no difference in incidence of death or retransplantation between ABO-compatible and ABO-incompatible HT in patients who underwent transplantation after 2005.
在过去,ABO 血型不相容被认为是成人心脏移植(HT)的绝对禁忌证。儿科患者的 ABO 血型不相容 HT 以及成人的 ABO 血型不相容腹部移植方面的进展,促使临床探索成人的有意 ABO 血型不相容 HT。然而,ABO 血型不相容的成人心脏移植受者的结局与 ABO 血型相容受者的结局相比,情况如何,尚不得而知。
我们分析了 1988 年至 2011 年间进行的心脏供体和受体均≥18 岁的国际心肺移植协会移植登记数据。我们比较了 ABO 血型不相容和 ABO 血型相容 HT 受者的基线特征和移植后结局。死亡或再次移植是复合的主要终点。
在 1988 年至 2011 年 6 月 30 日期间接受 HT 的 76663 例成人患者中,进行了 94 例 ABO 血型不相容心脏移植。ABO 血型不相容组的死亡或再次移植发生率高于 ABO 血型相容组:30 天为 21%比 9%(危险比=2.38,p<0.001),1 年为 36%比 19%。然而,在移植后 1 年以上存活的 ABO 血型不相容移植物的失败发生率与 ABO 血型相容组相似。2005 年后,成人 ABO 血型不相容 HT 的比例增加,可能是由于计划的、有意的(而非意外的)ABO 血型不相容 HT。在这组患者中,30 天和 1 年后的死亡或再次移植的短期和长期发生率与 ABO 血型相容受者相似(p=0.822):分别为 7%和 19%。
我们发现,2005 年后接受移植的患者中,ABO 血型相容和 ABO 血型不相容 HT 的死亡或再次移植发生率无差异。